Below you can familiarize yourself with the publications from Mika Kontro's research group.
Selected publications
- Kuusanmäki H, Kytölä S, Vänttinen I, Ruokoranta T, Ranta A, et al.. Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia. Haematologica 2022.
- Kuusanmäki H, Dufva O, Vähä-Koskela M, Leppä AM, Huuhtanen J, et al.. Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia. Blood 2022
- Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A. et al. Individualized Systems Medicine (ISM) strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discovery 2013
- Kontro M, Kumar A, Majumder MM, Eldfors S, Parsons A, Pemovska T et al. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. Leukemia 2017
- Kuusanmäki H, Leppä AM, Pölönen P, Kontro M et al. Phenotype-based drug testing reveals maturation stage-dependent sensitivity to BCL2 inhibitor venetoclax in AML. Haematologica 2020
- Kontro M*, Kuusanmäki H*, Eldfors S, Burmeister T, Andersson EI, Brümmendorf TH, Edgren H, et al. Novel activating STAT5B mutations as putative drivers of acute lymphoblastic leukemia. Leukemia 2014
Mika Kontro's latest publications